Poster at ADLM: Development of glycosylation independent NT proBNP turbidimetric assay

Ground-breaking assay development to measure the total level of NT-proBNP, independent of glycosylation

Don't miss the opportunity to delve deeper into this ground-breaking development and engage with us at the poster session: A-010. Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP

Development of a turbidimetric NT-proBNP assay which is not affected by glycosylation

In the poster titled: Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP(A-010)we present a comparison of Gentian's assay with other commercially available immunoassays. This comparison focuses on effect of glycosylation on detection of NT-proBNP in patient samples.

To investigate the effect of glycosylation, plasma samples were either non-treated or treated with a mixture of glycosidases. No significant effect of the glycosidase treatment was detected on NT-proBNP values measured by the prototype of Gentian-developed NT-proBNP assay. NT-proBNP concentrations in both treated and non-treated samples were similar and highly correlated. As a comparison, one of the commercially available assays, which uses antibodies targeting the central region of the NT-proBNP, was studied. The results show significant difference between levels measured before- and after treatment with glycosydases and confirms the underestimation of NT-proBNP concentration.

Glycosylation

Multiple commercial immunoassays are available for measurement of circulating NT-proBNP levels, used as an aid in diagnosis and severity assessment of heart failure (HF). Most of these assays use antibodies that bind to the central region of NT-proBNP, which is normally glycosylated. It has been shown that up to 80% of the NT-proBNP may be glycosylated in the central region. The glycosylation restricts antibody binding and protein detection, leading to an underestimation of NT-proBNP levels.

Advantages of Immunoassays Targeting Glycosylation-Free Regions of NT-proBNP in Heart Failure Diagnosis and Management.

Given the considerable variability in levels and site occupancy of O-glycosylated proteins, it is reasonable to anticipate that immunoassays targeting glycosylation-free regions of NT-proBNP may offer advantages in HF diagnosis and prognosis for specific patient groups and disease states since these assays can detect endogenous NT-proBNP regardless of its glycosylation status.

Gentian's turbidimetric NT-proBNP assay enters the final stages of optimisation phase

Several NT-proBNP assays are already available on chemiluminescence-based diagnostic platforms. Gentian's goal is to make NT-proBNP analysis more accessible on high-volume clinical chemistry analysers, improving cost- and workflow efficiency

Extensive testing of our prototype confirms the hypothesis that the glycosylation of the NT-proBNP molecule can lead to an underestimation of NT-proBNP concentrations in clinical samples, as seen with commercially available assays. Gentian's NT-proBNP assay is designed to detect endogenous NT-proBNP regardless of its glycosylation status, avoiding potential underestimation of the protein.

Get in touch with Gentian

Want to know more? Meet us at booth #3201 at ADLM 2024. Book a meeting by sending an email to [email protected] or fill out the form below:

Public link

Please use the above public link if you want to share this noodl on another website.